<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JMDS</journal-id><journal-title-group><journal-title>Journal of Medicines Development Sciences</journal-title></journal-title-group><issn>2382-6363</issn><eissn>2382-6371</eissn><publisher><publisher-name>WHIOCE PUBLISHING PTE. LTD.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18063/JMDS.v10i4.1177</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Lenacapavir impurity analysis</title><url>https://artdesignp.com/journal/JMDS/10/4/10.18063/JMDS.v10i4.1177</url><author>WangQingsong,QiuYongfeng</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>10</volume><issue>4</issue><history><date date-type="pub"><published-time>2025-12-26</published-time></date></history><abstract>On June 20, 2024, Gilead Sciences announced the interim results of the pivotal Phase 3 PURPOSE 1 trial for Lenacapavir, a new HIV prevention drug administered via subcutaneous injection twice a year, demonstrating 100% efficacy in preventing HIV infection in young women.On August 22, 2022, the European Commission approved Lenacapavir globally for use in combination with other antiretroviral drugs to treat adult HIV-infected patients with multidrug-resistant virus who cannot achieve viral suppression.The synthesis of the key intermediate LNKPW01 for Linaclotide involves the Suzuki reaction, during which we identified several impurities. Through in-depth investigation of these impurities, we gained a deeper understanding of the process. Let's take a closer look at these impurities, with impurity M being the most significant.</abstract><keywords>Lenvatinib, Process, Impurities</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>[1]&amp;nbsp;Emmons W&amp;nbsp;D, 1961,&amp;nbsp;Peroxides. IV. Polypeoxides. J. Am. Chem. Soc,&amp;nbsp;83(7): 1733&amp;ndash;1738.
[2]&amp;nbsp;Bothner-By A&amp;nbsp;A, Foote C S, 1961, Rates of Reaction of Diphenylpicrylhydrazyl with Phenols and Amines. J. Am. Chem. Soc,&amp;nbsp;83(10): 2164&amp;ndash;2166.
[3] Toyoda K, Tashiro&amp;nbsp;S, Takeuchi MT, 2021, Discovery of a Peptide Nucleation Factor for Digestive Organelle Formation. J. Am. Chem. Soc,&amp;nbsp;143(7): 2818&amp;ndash;2827.
[4] Hoffmann H&amp;nbsp;M&amp;nbsp;R, Heiermann K E K, 1978,&amp;nbsp;Reaction of &amp;alpha;,&amp;beta;-Unsaturated Carbonyl Compounds with Diazoalkanes. J. Org. Chem,&amp;nbsp;43(8): 1619&amp;ndash;1620.
[5] Li W, Wang&amp;nbsp;Y, Wang Z&amp;nbsp;A, 2014,&amp;nbsp;Continuous Process for the Production of &amp;gamma;-Butyrolactone. Org. Process Res. Dev,&amp;nbsp;18(3): 501&amp;ndash;510.
[6] Grissom J&amp;nbsp;W,&amp;nbsp;Klingberg D, 1996,&amp;nbsp;Tandem Radical Cyclization-Rearrangement Reactions. J. Org. Chem,&amp;nbsp;61(7): 2346&amp;ndash;2351.
[7] Grieco P A, Henry K J, 2003,&amp;nbsp;An Efficient Synthesis of cis-2,5-Disubstituted Pyrrolidines. Tetrahedron Lett,&amp;nbsp;44(9):&amp;nbsp;154&amp;ndash;1544.
[8] Zhang W, Curran D P, 2006, Synthesis of Fluorous Oxazolidinones and Their Use in Enantioselective Aldol Reactions. J. Am. Chem. Soc,128(21): 6829&amp;ndash;6836.
[9] Shi F, Tse M K, 2009, Copper-Catalyzed Enantioselective Henry Reaction. Angew. Chem., Int. Ed ,48(32): 5912&amp;ndash;5915.
[10] Zhu W, Mena M, No&amp;euml;l S, 2011,&amp;nbsp;Synthesis of&amp;nbsp;2-Amino-3-cyano-4H-chromenes. Tetrahedron ,67(12): 2332&amp;ndash;2337.
[11] Ragan J A, am Ende D J, Hill P D,&amp;nbsp;2007, Development of a Safe and Scalable Process for a Key Intermediate. Org. Process Res. Dev,11(5):&amp;nbsp;799&amp;ndash;805.
[12] Wu Z,&amp;nbsp;Yu J, Wu J, 2020, Continuous-Flow Synthesis of a Pharmaceutical Intermediate. Org. Process Res. Dev,&amp;nbsp;24(2): 228&amp;ndash;234.
[13] Bryan M C, Dunn P J, 2018, Key Green Chemistry Research Areas from a Pharmaceutical Perspective. Org. Process Res. Dev,&amp;nbsp;22(4): 542&amp;ndash;584.
[14] Ma S, Gu Z, 2006, Palladium-Catalyzed Cyclization of 1,3-Dienes. Chem. Commun, (1): 94&amp;ndash;96.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
